About the Melanoma Session
Melanoma is the deadliest and most aggressive type of skin cancer. Melanoma develops when melanocytes, the pigment-producing cells present in the skin, eye, inner ear, and leptomeninges, acquire genetic mutations. UV radiation is the primary cause of melanoma in people who have low amounts of the skin pigment melanin. Any skin lesion that has indications of being potentially malignant is biopsied and analyzed for diagnosis. Melanoma, a malignant cancer emerging from melanocytes, is a rare disease in the United States, affecting only 22.1 persons per 100,000. It is, nevertheless, a notably deadly disease, accounting for 75% of skin cancer deaths despite only accounting for 4% of skin cancer cases. The mnemonic "ABCDEF" summarizes the early signs of melanoma: Asymmetry, Borders (irregular with edges and corners), Color (variegated), Diameter (greater than 6 mm (0.24 in), Evolving over time
- Metastatic Melanoma
- Malignant Melanoma
- Combat Melanoma
- Scleroderma
- Biomarkers
Featured Speakers — Melanoma 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Melanoma Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Melanoma Conference 2027
Present Your Research
Oral and poster slots for original Melanoma work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Melanoma research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same program, same certificate.
Join IDC 2027 for the Melanoma track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Melanoma Conference 2027 — FAQs
What is the Melanoma track at IDC 2027?
The Melanoma track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Melanoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Melanoma sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Melanoma are all welcome — whether presenting or attending.
Can I present my research in the Melanoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Melanoma sessions?
Yes. IDC 2027 is a hybrid conference — attend the Melanoma track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.